Biogen Inc. (FRA:IDP)
Germany · Delayed Price · Currency is EUR 121.65
-0.25 (-0.21%)
Last updated: Sep 9, 2025, 5:35 PM CET
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
€1,119,322
Profits / Employee
€171,364
Market Cap
17.97B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7,605 | 35 | 0.46% |
| Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
| Dec 31, 2022 | 8,725 | -885 | -9.21% |
| Dec 31, 2021 | 9,610 | 510 | 5.60% |
| Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| SAP SE | 109,121 |
| Siemens Aktiengesellschaft | 327,000 |
| Deutsche Telekom AG | 198,194 |
| Allianz SE | 156,626 |
| Rheinmetall AG | 28,539 |
| Siemens Energy AG | 98,000 |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Biogen News
- 1 day ago - Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 days ago - Biogen (BIIB) Analyst Ratings Update: September 4, 2025 | BIIB Stock News - GuruFocus
- 6 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 6 days ago - Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
- 6 days ago - Biogen (BIIB) Seeks FDA Expansion for Alzheimer's Drug Autoinjector - GuruFocus
- 6 days ago - Biogen, Eisai begin rolling FDA submissions for Leqembi injectable for starting dose - Seeking Alpha
- 7 days ago - Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - Benzinga
- 7 days ago - Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status - Wallstreet:Online